Drug
JNJ-47910382 clinical trials
Also written JNJ-47910382.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses JNJ-47910382 is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected PatientsTerminatedPhase 1Janssen R&D IrelandNCT01586325Written as JNJ-47910382 30 mg
- Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382TerminatedPhase 1Janssen R&D IrelandNCT01651767Written as JNJ-47910382
- A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy ParticipantsCompletedPhase 1Janssen R&D IrelandNCT01662661Written as JNJ-47910382 (tablet)
- A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382CompletedPhase 1Janssen R&D IrelandNCT01482611Written as JNJ-47910382